Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 4/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | CMKLR1 | Q99788 | 5/20 | 0.33 |
| ▸ | ATR | Q13535 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12429913 | 0.82 | HRH3 (0.35) | CYP4F2CYP4A11RETATR | |
| SCHEMBL2306776 | 0.81 | HTR3A (0.42) | CYP4F2CYP4A11HTR3ACMKLR1ATR | |
| SCHEMBL176897 | 0.80 | CYP4F2 (0.40) | CYP4F2CYP4A11ESR1RETDGAT2 | |
| SCHEMBL176922 | 0.75 | CYP4F2 (0.42) | CYP4F2CYP4A11ESR1RETDGAT2 | |
| SCHEMBL257733 | 0.74 | ELANE (0.47) | CYP4F2CYP4A11GAA | |
| SCHEMBL24012457 | 0.73 | CYP4F2 (0.46) | CYP4F2CYP4A11ESR1RETDGAT2 | |
| SCHEMBL18823955 | 0.72 | HTR3A (0.40) | CYP4F2CYP4A11DGAT2HTR3ARXRA | |
| SCHEMBL13323759 | 0.72 | HRH3 (0.39) | CYP4F2CYP4A11RET | |
| SCHEMBL2303237 | 0.72 | HTR3A (0.44) | CYP4F2CYP4A11HTR3ACMKLR1ATR | |
| SCHEMBL18823917 | 0.71 | CYP4F2 (0.40) | CYP4F2CYP4A11ESR1RETDGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2351742-A1 | INDAZOLE DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2011-08-03 | — | — | EP | claimed |
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-17 | — | — | US | claimed |
| US-8304443-B2 | Indazole derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304443-B2 | Indazole derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304443-B2 | Indazole derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-11-06 | — | — | US | disclosed |
| EP-2351742-A1 | INDAZOLE DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-17 | — | — | US | disclosed |
| WO-2010041568-A1 | INDAZOLE DERIVATIVE | 旭化成ファーマ株式会社 (JP) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ADRB3, INSR, ADRB1 | CYP4F2 937/4885CYP4A11 137/4885ESR1 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.